Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694298 | 1.00 | TP53 (0.40) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL30751933 | 0.97 | TP53 (0.42) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL15834924 | 0.88 | TP53 (0.44) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1572816 | 0.88 | TP53 (0.44) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13635791 | 0.88 | TP53 (0.44) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18211012 | 0.87 | TP53 (0.50) | TP53SLC7A5 | |
| SCHEMBL1261744 | 0.81 | TP53 (0.50) | TP53SLC7A5 | |
| Ammonia Solution, Strong SCHEMBL8858520 | 0.78 | TP53 (0.47) | TP53SLC7A5 | |
| Ammonia Solution, Strong SCHEMBL8858522 | 0.78 | TP53 (0.47) | TP53SLC7A5 | |
| SCHEMBL2343605 | 0.77 | TP53 (0.40) | TP53SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0925792-B1 | Insoluble insulin compositions for controlling blood glucose | LILLY CO ELI (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-1396272-A1 | Insoluble Insulin Compositions for Controlling Blood Glucose | Eli Lilly & Company (US) | 2004-03-10 | — | — | EP | disclosed |
| US-20030144181-A1 | Insoluble compositions for controlling blood glucose | BRADER MARK LAURENCE (US) | 2003-07-31 | — | — | US | disclosed |
| US-6531448-B1 | Composition comprising protein selected from insulin, insulin analog, and proinsulin; derivatized protein selected from fatty acid-acylated insulins; complexing compound; hexamer stabilizing compound; and divalent metal cation | ELI LILLY AND COMPANY | 2003-03-11 | — | — | US | disclosed |
| US-6465426-B2 | ACYLATION | ELI LILLY AND COMPANY | 2002-10-15 | — | — | US | disclosed |
| US-20020082199-A1 | Insoluble insulin compositions | BRADER MARK LAURENCE (US) | 2002-06-27 | — | — | US | disclosed |
| EP-1196446-A1 | PROTAMINE-FREE INSOLUBLE ACYLATED INSULIN COMPOSITIONS | ELI LILLY AND COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| US-20010036916-A1 | Insoluble insulin compositions | BRADER MARK LAURENCE (US) | 2001-11-01 | — | — | US | disclosed |
| US-6268335-B1 | MICROCRYSTAL COMPRISING (A) DERIVIATED INSULIN, DERIVIATED INSULIN ANALOGS, OR DERIVIATED PROINSULINS; (B) A COMPLEXING COMPOUND; (C) A HEXAMER-STABILIZING COMPOUND; AND (D) A DIVALENT METAL CATION. | ELI LILLY AND COMPANY | 2001-07-31 | — | — | US | disclosed |
| WO-2001000675-A1 | PROTAMINE-FREE INSOLUBLE ACYLATED INSULIN COMPOSITIONS | ELI LILLY AND COMPANY (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-1999032116-A1 | INSOLUBLE COMPOSITIONS FOR CONTROLLING BLOOD GLUCOSE | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0925792-A2 | Insoluble compositions for controlling blood glucose | ELI LILLY AND COMPANY (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999021578-A1 | INSOLUBLE INSULIN COMPOSITIONS | ELI LILLY AND COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
| EP-0911035-A2 | INSOLUBLE INSULIN COMPOSITIONS | ELI LILLY AND COMPANY (US) | 1999-04-28 | — | — | EP | disclosed |